

Glioblastoma Multiforme Treatment-EMEA Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/G766BF73388EN.html

Date: January 2018 Pages: 149 Price: US\$ 3,480.00 (Single User License) ID: G766BF73388EN

Abstracts

Report Summary

Glioblastoma Multiforme Treatment-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Glioblastoma Multiforme Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Glioblastoma Multiforme Treatment 2013-2017, and development forecast 2018-2023

Main market players of Glioblastoma Multiforme Treatment in EMEA, with company and product introduction, position in the Glioblastoma Multiforme Treatment market Market status and development trend of Glioblastoma Multiforme Treatment by types and applications

Cost and profit status of Glioblastoma Multiforme Treatment, and marketing status Market growth drivers and challenges

The report segments the EMEA Glioblastoma Multiforme Treatment market as:

EMEA Glioblastoma Multiforme Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe Middle East



Africa

EMEA Glioblastoma Multiforme Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Bevacizumab (Avastin) Temozolomide (Temodar and Temodal and Temcad) Carmustine (BiCNU)

EMEA Glioblastoma Multiforme Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital Clinic

EMEA Glioblastoma Multiforme Treatment Market: Players Segment Analysis (Company and Product introduction, Glioblastoma Multiforme Treatment Sales Volume, Revenue, Price and Gross Margin):

AbbVie, Inc Activartis GmbH Agenus Inc Arog Pharmaceuticals, Inc Bristol-Myers Squibb Company Cavion LLC Celldex Therapeutics Inc Cortice Biosciences Exelixis Inc F. Hoffmann-La Roche Ltd

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF GLIOBLASTOMA MULTIFORME TREATMENT

- 1.1 Definition of Glioblastoma Multiforme Treatment in This Report
- 1.2 Commercial Types of Glioblastoma Multiforme Treatment
- 1.2.1 Bevacizumab (Avastin)
- 1.2.2 Temozolomide (Temodar and Temodal and Temcad)
- 1.2.3 Carmustine (BiCNU)
- 1.3 Downstream Application of Glioblastoma Multiforme Treatment
- 1.3.1 Hospital
- 1.3.2 Clinic
- 1.4 Development History of Glioblastoma Multiforme Treatment
- 1.5 Market Status and Trend of Glioblastoma Multiforme Treatment 2013-2023
- 1.5.1 EMEA Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023

1.5.2 Regional Glioblastoma Multiforme Treatment Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Glioblastoma Multiforme Treatment in EMEA 2013-2017
- 2.2 Consumption Market of Glioblastoma Multiforme Treatment in EMEA by Regions

2.2.1 Consumption Volume of Glioblastoma Multiforme Treatment in EMEA by Regions

2.2.2 Revenue of Glioblastoma Multiforme Treatment in EMEA by Regions2.3 Market Analysis of Glioblastoma Multiforme Treatment in EMEA by Regions

- 2.3.1 Market Analysis of Glioblastoma Multiforme Treatment in Europe 2013-2017
- 2.3.2 Market Analysis of Glioblastoma Multiforme Treatment in Middle East 2013-2017

2.3.3 Market Analysis of Glioblastoma Multiforme Treatment in Africa 2013-20172.4 Market Development Forecast of Glioblastoma Multiforme Treatment in EMEA2018-2023

2.4.1 Market Development Forecast of Glioblastoma Multiforme Treatment in EMEA 2018-2023

2.4.2 Market Development Forecast of Glioblastoma Multiforme Treatment by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole EMEA Market Status by Types



3.1.1 Consumption Volume of Glioblastoma Multiforme Treatment in EMEA by Types

3.1.2 Revenue of Glioblastoma Multiforme Treatment in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Glioblastoma Multiforme Treatment in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Glioblastoma Multiforme Treatment in EMEA by Downstream Industry

4.2 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Europe

4.2.2 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Middle East

4.2.3 Demand Volume of Glioblastoma Multiforme Treatment by Downstream Industry in Africa

4.3 Market Forecast of Glioblastoma Multiforme Treatment in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

5.1 EMEA Economy Situation and Trend Overview

5.2 Glioblastoma Multiforme Treatment Downstream Industry Situation and Trend Overview

CHAPTER 6 GLIOBLASTOMA MULTIFORME TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Glioblastoma Multiforme Treatment in EMEA by Major Players
6.2 Revenue of Glioblastoma Multiforme Treatment in EMEA by Major Players
6.3 Basic Information of Glioblastoma Multiforme Treatment by Major Players
6.3.1 Headquarters Location and Established Time of Glioblastoma Multiforme
Treatment Major Players



6.3.2 Employees and Revenue Level of Glioblastoma Multiforme Treatment Major Players

- 6.4 Market Competition News and Trend
- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 GLIOBLASTOMA MULTIFORME TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 AbbVie, Inc
- 7.1.1 Company profile
- 7.1.2 Representative Glioblastoma Multiforme Treatment Product
- 7.1.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of AbbVie, Inc

7.2 Activartis GmbH

- 7.2.1 Company profile
- 7.2.2 Representative Glioblastoma Multiforme Treatment Product
- 7.2.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of

Activartis GmbH

7.3 Agenus Inc

- 7.3.1 Company profile
- 7.3.2 Representative Glioblastoma Multiforme Treatment Product
- 7.3.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Agenus Inc
- 7.4 Arog Pharmaceuticals, Inc
 - 7.4.1 Company profile
 - 7.4.2 Representative Glioblastoma Multiforme Treatment Product
- 7.4.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Arog Pharmaceuticals, Inc
- 7.5 Bristol-Myers Squibb Company
 - 7.5.1 Company profile
 - 7.5.2 Representative Glioblastoma Multiforme Treatment Product
- 7.5.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

7.6 Cavion LLC

- 7.6.1 Company profile
- 7.6.2 Representative Glioblastoma Multiforme Treatment Product
- 7.6.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of



Cavion LLC

7.7 Celldex Therapeutics Inc

7.7.1 Company profile

7.7.2 Representative Glioblastoma Multiforme Treatment Product

7.7.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Celldex Therapeutics Inc

7.8 Cortice Biosciences

7.8.1 Company profile

7.8.2 Representative Glioblastoma Multiforme Treatment Product

7.8.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Cortice Biosciences

7.9 Exelixis Inc

7.9.1 Company profile

7.9.2 Representative Glioblastoma Multiforme Treatment Product

7.9.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of Exelixis Inc

- 7.10 F. Hoffmann-La Roche Ltd
- 7.10.1 Company profile
- 7.10.2 Representative Glioblastoma Multiforme Treatment Product
- 7.10.3 Glioblastoma Multiforme Treatment Sales, Revenue, Price and Gross Margin of
- F. Hoffmann-La Roche Ltd

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 8.1 Industry Chain of Glioblastoma Multiforme Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT

- 9.1 Cost Structure Analysis of Glioblastoma Multiforme Treatment
- 9.2 Raw Materials Cost Analysis of Glioblastoma Multiforme Treatment
- 9.3 Labor Cost Analysis of Glioblastoma Multiforme Treatment
- 9.4 Manufacturing Expenses Analysis of Glioblastoma Multiforme Treatment

CHAPTER 10 MARKETING STATUS ANALYSIS OF GLIOBLASTOMA MULTIFORME TREATMENT



- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Glioblastoma Multiforme Treatment-EMEA Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/G766BF73388EN.html</u>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G766BF73388EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970